Last updated on April 2012

TPF Induction With Concomitant Chemoradiation to Treat Patients With Head and Neck Cancer


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Head and Neck Cancer
  • Age: Between 18 - 65 Years
  • Gender: Male or Female
  • Other:
    Histology and staging disease
    Histologically or cytologically proven non-metastatic locally advanced HNSCC, stage
    III or IV, for which concomitant chemo-radiotherapy would be the standard therapy
    Patients can be included either with irresectable disease or for which the
    concomitant chemoradiotherapy was chosen for organ preservation
    Measurable disease
    Primary site: oral cavity, oropharynx, hypopharynx and larynx
    General conditions
    Written informed consent
    Age >18 years and ≤ 65 years
    WHO performance status 0-1
    Adequate bone marrow function (WBC > 3.0 x 109/L, platelets > 100 x 109/L, Hb > 6
    mmol/L)
    Adequate hepatic function: total bilirubin < 1. 5 x upper normal limit, ASAT and ALAT
    < 2.5 x upper normal limits
    Adequate renal function: calculated creatinin clearance > 60ml/min. (Cockcroft-Gault
    formula) Other
    Expected adequacy of follow-up.

You may not be eligible for this study if the following are true:

  • General conditions
    Active alcohol addiction
    Admission for COPD in the last 12 months
    Weight loss > 10% in 3 months before entry
    Pregnancy or lactation
    Patients (M/F) with reproductive potential not implementing adequate contraceptives
    measures
    Prior or current history
    Prior surgery, radiotherapy or chemotherapy for this tumor
    Serious concomitant diseases preventing the safe administration of chemotherapy
    and/or radiotherapy or likely to interfere with the study assessments
    Serious active infections
    Other malignancies in the past 5 years with the exception of adequately treated
    carcinoma in situ of the cervix, or squamous or basal cell carcinoma of the skin
    Concomitant treatments
    Concomitant (or within 4 weeks before randomisation) administration of any other
    experimental drug under investigation
    Concurrent treatment with any other anti-cancer therapy

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.